At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.
|Articles|February 14, 2023
Supplements and Featured Publications
- Evolving Considerations for Choice of Hepatitis B Vaccine
Participating Faculty: Evolving Considerations for Choice of Hepatitis B Vaccine
Advertisement
Faculty
Neil Shieh, PharmD
Consultant
Medical Affairs & HEOR
COEUS Consulting Group
Devon, PA
Dalga D. Surofchy, PharmD
Clinical Manager
Medical Affairs & HEOR
COEUS Consulting Group
Devon, PA
Iris Tam, PharmD
Vice President
Head, Medical Affairs & HEOR
COEUS Consulting Group
Devon, PA
Faculty Disclosures
These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.
Neil Shieh, PharmD
RECEIPT OF PAYMENT FOR INVOLVEMENT IN THE PREPARATION OF THIS MANUSCRIPT
COEUS Consulting Group
Dalga D. Surofchy, PharmD
RECEIPT OF PAYMENT FOR INVOLVEMENT IN THE PREPARATION OF THIS MANUSCRIPT
COEUS Consulting Group
Iris Tam, PharmD
RECEIPT OF PAYMENT FOR INVOLVEMENT IN THE PREPARATION OF THIS MANUSCRIPT
COEUS Consulting Group
Articles in this issue
over 3 years ago
Evolving Considerations for Choice of Hepatitis B VaccineAdvertisement
Related to this article
Insulin icodec-abae becomes the first once-weekly basal insulin cleared for children 10 years and older with type 2 diabetes.
At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."
More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.
About 9% of adults hospitalized with RSV died in the hospital or within 30 days of discharge, according to preliminary data presented at IDWeek 2026.
A systematic review found vitamin D did not consistently reduce MS relapse rates, though some studies reported lower MRI lesion activity.
Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Real-World AMKD Data Highlight Quick Progression, Unmet Needs
3
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
4
Former USAID Health Chief Says Aid Cuts Are Costing Children's Lives
5